B of A Securities analyst Alastair Ryan downgrades UBS Gr (NYSE:UBS) from Buy to Neutral.
Belite Bio Seeks FDA Clearance For Late-Stage Genetic Eye Disease Study
Belite Bio (NASDAQ: BLTE) submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to support Phase 3 development of its lead asset LBS-008 for treatment of Stargardt Disease (STGD1).
,machine,Learning,With,Data,Mining,Technology,On,Virtual_8-260x195.jpeg)
